Cells are as unique as the researchers who study them. Using single-cell genomics applications, researchers are able to identify differences between individual cells in a seemingly homogeneous population.
Fluidigm has developed an entirely new approach to single-cell genomics based on microfluidic technology. Our innovative technologies enable highly parallel RNA and DNA analysis from samples containing only a few hundred cells. By integrating and simplifying multiple steps in the single-cell workflow, you can rapidly and reliably isolate, process and profile individual cells for multiple genomics applications.
Single-Cell Genomics
Single-Cell Proteomics
Related Products
Insights
Linking T Cell Clonotype to Phenotype Webinar
In the April 2016 issue of Nature Methods, scientists at the European Molecular Biology Laboratory–European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute (WTSI) published a new approach for single-cell TCR sequencing—an approach that can bring new insights about the response to immunotherapies and cancer vaccines, autoimmune disease, allergy and vaccine design and efficacy.
Passion, Imagination & CyTOF
It's easy to imagine Sean Bendall, PhD, on a "40 Under 40" list. An assistant professor previously affiliated with Stanford's Nolan Lab at the National Heart Lung and Blood Institute (NHLBI) Proteomics Center in Palo Alto, California, Bendall is a young standout and proof that the status quo will no longer do. He's in the forefront of a new movement that uses technology to advance single-cell biology...
Pioneering Immune Therapy Research
The first commercially available Fluidigm® C1™ system was purchased in 2012 by the Benaroya Research Institute at Virginia Mason (BRI) in Seattle, known worldwide for its autoimmune disease research. To mark the event, Fluidigm employees including the R&D team that brought the technology to life signed the shipping box containing the instrument.
Speaking Cell to Cell
A team of scientists at the Broad Institute and Fluidigm, led by Broad core member Aviv Regev, associate member Hongkun Park and our own Joe Shuga, analyzed the transcriptomes of more than 1,700 primary mouse bone-marrow-derived dendritic cells, revealing a subpopulation of "precocious" cells that expressed antiviral genes earlier in the immune process than others.
One Cell at a Time
The ability to isolate and study individual cells using the leading-edge technology of our C1™ system enables researchers across disciplines to explore the heterogeneity of cell populations. Recently a team of scientists at the Broad Institute and Fluidigm analyzed transcriptomes of more than 1,700 primary mouse bone-marrow-derived dendritic cells...